Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more ...

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other ...

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove ...

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S ...

Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced ...

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching ...

Drugmakers including BioNTech, Merck & Co. and Pfizer are all testing their investigational PD-1/VEGF bispecifics against ...

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically ...

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance ...

A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as ...